Imunon (NASDAQ:IMNN) Upgraded by EF Hutton Acquisition Co. I to “Strong-Buy”

Imunon (NASDAQ:IMNN) was upgraded by analysts at EF Hutton Acquisition Co. I to a “strong-buy” rating in a report released on Monday, Zacks.com reports.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $14.00 target price on shares of Imunon in a report on Thursday, August 15th.

Imunon Price Performance

Shares of NASDAQ IMNN opened at $1.03 on Monday. The company has a 50 day simple moving average of $1.20 and a 200 day simple moving average of $1.26. Imunon has a 1 year low of $0.48 and a 1 year high of $3.65. The firm has a market cap of $61.85 million, a PE ratio of -0.51 and a beta of 2.13.

Imunon (NASDAQ:IMNN) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.51) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.04. As a group, research analysts anticipate that Imunon will post -1.71 earnings per share for the current fiscal year.

Imunon Company Profile

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.